New indication
Colin Kerr
Published: Wednesday, May 1, 2019
ILUVIEN® has been approved for use in UK patients for the prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).
“This indication for ILUVIEN was based on data from two three-year, double-masked, prospective sham-controlled studies, PSV-FAI-001 and PSV-FAI-005, in 282 patients with NIU-PS, randomised 2:1 (ILUVIEN:sham). Published data from the PSV-FAI-001 study have shown ILUVIEN to be superior when compared to treated sham for multiple study outcomes, including the primary outcome of recurrence of NIU-PS at six months (27.6% ILUVIEN vs 90.5% sham, p<0.001),” said a spokesman for Alimera Sciences, manufacturers of ILUVIEN.
alimerasciences.com
Latest Articles
Simulators Benefit Surgeons and Patients
Helping young surgeons build confidence and expertise.
How Many Surgeries Equal Surgical Proficiency?
Internet, labs, simulators, and assisting surgery all contribute.
Improving Clinical Management for nAMD and DME
Global survey data identify barriers and opportunities.
Are Postoperative Topical Antibiotic Drops Still Needed?
Cataract surgeons debate the benefits of intracameral cefuroxime prophylaxis.
Emerging Technology for Detecting Subclinical Keratoconus
Brillouin microscopy shows promise in clinical studies.
Knowing Iris Repair: Modified Trifold Technique
Part eight of our series covers the modified trifold technique for large iris defects.
It’s All About Biomechanics!
Increasing the pool of patients eligible for refractive surgery.
Uncovering More Safe and Quick Options
Different strategies, such as PresbyLASIK, can offer presbyopes good outcomes.
Topography-Guided PRK for Keratoconus
Improving visual acuity in patients with keratoconus.
Defining AMD Treatment Protocol
Treatments trending to fewer injections for better results.